Justin Kim
Stock Analyst at Oppenheimer
(1.02)
# 3,748
Out of 4,959 analysts
37
Total ratings
41.38%
Success rate
-11.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Outperform | $17 → $16 | $2.01 | +696.02% | 2 | Aug 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $27.97 | +43.01% | 6 | Nov 6, 2024 | |
| PHVS Pharvaris | Maintains: Outperform | $38 → $42 | $23.12 | +81.66% | 4 | Sep 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $38.34 | +176.47% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $32.93 | +164.20% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $22.57 | +15.20% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $5.81 | - | 2 | Oct 17, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $12.27 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $8.56 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $42.69 | +38.21% | 1 | Jul 18, 2022 |
Zura Bio
Aug 15, 2025
Maintains: Outperform
Price Target: $17 → $16
Current: $2.01
Upside: +696.02%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $27.97
Upside: +43.01%
Pharvaris
Sep 6, 2024
Maintains: Outperform
Price Target: $38 → $42
Current: $23.12
Upside: +81.66%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $38.34
Upside: +176.47%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $32.93
Upside: +164.20%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $22.57
Upside: +15.20%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $5.81
Upside: -
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $12.27
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $8.56
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $42.69
Upside: +38.21%